You are on primary menu. Click to skip to content
Anxiety, Behavioral Healthcare, CBT, Cognitive Behavioral Therapy, DCBT, Depression, Digital Cognitive Behavioral Therapy, digital emotional wellbeing, evidence-based behavioral healthcare, evidence-based mental healthcare, FearFighter®, GAD-7, Generalized Anxiety Disorder Assessment, Mental Illness, MoodCalmer, NeuroFlow, pandemic, panic, Patient Health Questionnaire, phobia, PHQ-9, SAMHSA, Substance Abuse and Mental Health Services Administration, youth mental health crisis
acceptance and commitment therapy, ACT, Anxiety, CBT, chronic pain, Cognitive Behavioral Therapy, ComfortAble®, DBT, DCBT, Depression, dialectical behavior therapy, Digital Cognitive Behavioral Therapy, drugs, EDMR, ERP, esketamine, Evidence-based, evidence-informed, exposure and response prevention therapy, eye movement desensitization and reprocessing therapy, FearFighter®, fluoxetine, Insomnia, intervention, Magellan Federal, Magellan Health, Magellan Healthcare, medication, mental health and wellness apps, MoodCalmer, pregabalin, psychotropic, RDx, response disequilibrium therapy, RESTORE, risperidone, Schizophrenia, SHADE, sleep difficulties, Substance use disorder, TMS, transcranial magnetic stimulation, treatment
AJMC, American Journal of Managed Care, American Psychiatric Association, American Psychiatric Association 2018 Annual Meeting, APA, APA 2018 Annual Meeting, CCBT, Cobalt, DCBT, Digital Cognitive Behavioral Therapy, Digital healthcare, Future of Healthcare, healthcare innovation, Magellan, Magellan Health, Magellan Healthcare, Magellan in the News, Magellan RX, RESTORE, Seth Feuerstein
